It has been well-documented that activation of the erbB3 signaling plays a pivotal role in the development of erbB2+ breast cancer [14,15], castration-resistant prostate cancer [36], platinum resistant/refractory ovarian cancer [37,38], and etc. Nonetheless, no erbB3-targeted therapy has been approved for cancer treatment. This evidence concerns the gene ERBB2 and cancer.